The Research Library

Most lion's mane research begins with two families of compounds — hericenones in the fruiting body, erinacines in the mycelium — that stimulate production of nerve growth factor in cell and animal studies. That mechanism is real and repeatable in the lab.

What is thinner is the human record: a handful of small trials, mostly in older adults with mild cognitive concerns, measuring performance on cognitive tests over weeks to months. The honest summary is that the biology is interesting, the human evidence is early, and the strongest claims in supplement advertising are not the claims the studies make.

• What studies examine

  Nerve growth factor stimulation; cognitive test scores in small human trials.

• What's supported

  Preclinical NGF stimulation, consistently; early human signals worth following.

• What isn't

  Large replicated trials, and anything about regenerating nerves in people.

Meet the mushroom

Reishi's traditional record runs about two thousand years, which is a long time for a reputation to survive without a marketing department. Modern research examines its triterpenes and polysaccharides, mainly for effects on immune signalling, sleep quality and fatigue.

The trials exist, but they are usually small, short, and often enrol people managing a specific condition rather than healthy volunteers. What is supported: measurable immune-marker changes and good tolerability at studied doses. What is not supported by the evidence so far: large trials in healthy adults, and certainly not the "mushroom of immortality" framing that sells so well.

• What studies examine

  Immune signalling, sleep quality and fatigue, mostly in small trials.

• What's supported

  Immune-marker changes and tolerability at studied doses.

• What isn't

  Large trials in healthy adults, or the immortality framing.

Meet the mushroom

Turkey tail is the deepest file in the cabinet. Its polysaccharide compound PSK was developed in Japan in the 1970s and has been studied in human trials for decades, largely as an adjunct given alongside standard cancer treatment rather than instead of it.

That history is why we grade it well-studied: there is real human data, gathered over a long period, by more than one research group. The caveat matters as much as the headline. It was studied as an adjunct, under clinical supervision, at doses measured in grams — not as a sprinkle in a mug. A coffee blend is a food, and we will never describe it as a treatment.

• What studies examine

  PSK as an adjunct therapy in human trials, chiefly in Japan.

• What's supported

  Decades of human data on immune function from more than one group.

• What isn't

  Use as a substitute for treatment, or effects at culinary doses.

Meet the mushroom

The wild fungus that started the legend grows out of caterpillars on the high plateau and costs more per pound than the coffee it would go into. Almost everything sold today is a cultivated species, Cordyceps militaris, grown on substrate — consistent, affordable, and a different organism from the wild one.

Research has looked at oxygen utilisation, fatigue and exercise performance. There are small human trials with genuinely promising results and an equally real failure to replicate them at scale, which is the definition of emerging rather than established. We include cordyceps for the lift and describe it exactly that way.

• What studies examine

  Oxygen utilisation, fatigue and exercise performance in small trials.

• What's supported

  Modest, promising signals on fatigue and performance.

• What isn't

  Replication at scale, and any claim about the wild fungus based on the cultivated one.

Meet the mushroom

Chaga is not a mushroom in the ordinary sense — it is a hardened conk that grows on birch in cold climates over many years, and much of what makes it interesting is borrowed from that birch: melanin, and compounds such as betulinic acid that come from the tree partnership.

The research is overwhelmingly lab and animal work on antioxidant activity and immune signalling. Human studies are scarce. Chaga is also the mushroom most often oversold, and the one with documented interactions worth raising with a clinician if you take regular medication. We use it in honest amounts and we do not lean on it in the marketing.

• What studies examine

  Antioxidant activity and immune signalling, mainly in lab and animal models.

• What's supported

  Interesting chemistry, and a long record of traditional use.

• What isn't

  Human outcome research; safe use alongside common medications.

Meet the mushroom

King trumpet (Pleurotus eryngii) is the largest of the oyster mushrooms, and its research file is the youngest in our blend. That is exactly the kind of thing we would rather say up front than paper over: early work examines its antioxidant compounds, lipid effects, and the erinacine-adjacent compounds that make oysters interesting, but large human trials do not exist yet.

What is well established is its history as a cultivated food and its role in the cup: structure, umami, and body. We grade it emerging because that is what the record shows — and we think a coffee company that grades one of its own ingredients "emerging" is telling you something about all the other grades on this page.

• What studies examine

  Antioxidant compounds, lipid and cholesterol markers — mostly preclinical or small.

• What's supported

  A long safe cultivated-food history; promising early work.

• What isn't

  Large replicated human trials. When they exist, this page updates.

Meet the mushroom